Skip to main content
SpringerLink
Log in

Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs)

  • Living reference work entry
  • First Online:
Hepato-Pancreato-Biliary Malignancies

  • 50 Accesses

Abstract

Neuroendocrine tumors (NETs) account for 2% of all malignancies in the United States. A subset of gastroenteropancreatic NETs are pancreatic neuroendocrine tumors (PNETs). PNETs now account for 7% of pancreatic malignancies in the United States in 2020. This chapter discusses the nonsurgical management of PNETs. Medical management for PNETs has improved tremendously and continues to evolve. Medical treatment involves therapy to control hormonal symptoms, decrease tumor burden, control tumor growth, and lengthen survival. Many options exist and require discussions with a multidisciplinary team including medical, surgical, oncological, endoscopic, and radiological treatments. Somatostatin therapy, liver-directed treatment, molecular targeted therapies, systemic chemotherapy, radiotherapy, and EUS-guided therapies are treatment modalities that must be considered when appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Simoneaux R. A look at the increasing incidence of neuroendocrine tumors. Oncol Times. 2020;42:1–4.

    Google Scholar 

  3. Key statistics for pancreatic neuroendocrine tumor. https://www.cancer.org/cancer/pancreatic-neuroendocrine-tumor/about/key-statistics.html.

  4. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol Lond Engl. 2010;6:229–37.

    Article  CAS  Google Scholar 

  5. Stueven AK, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20:3049.

    Article  CAS  PubMed Central  Google Scholar 

  6. Yao JC, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:69–76.

    Article  CAS  Google Scholar 

  7. Pavel ME, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017;28:1569–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:4656–63.

    Article  CAS  Google Scholar 

  9. Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

    Article  PubMed  Google Scholar 

  10. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69–74.

    Article  CAS  PubMed  Google Scholar 

  11. van der Hoek J, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638–45.

    Article  PubMed  Google Scholar 

  12. Wolin EM, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kaderli RM, et al. Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis. JAMA Oncol. 2019;5:480–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nigri G, et al. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Boeti MPS, Grigorie R, Popescu I. Laparoscopic radiofrequency ablation of liver tumors. Hepatic Surg. 2013; https://doi.org/10.5772/52830.

  17. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–9.

    Article  PubMed  Google Scholar 

  18. Koumarianou A, et al. Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology. 2015;101:274–88.

    Article  CAS  PubMed  Google Scholar 

  19. Strosberg JR, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.

    Article  CAS  PubMed  Google Scholar 

  20. Kunz PL, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36:4004.

    Article  Google Scholar 

  21. de Mestier L, et al. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor. Neuroendocrinology. 2020;110:83–91.

    Article  PubMed  Google Scholar 

  22. Ducreux M, et al. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – a phase II non-randomised trial. Eur J Cancer Oxf Engl. 2014;1990(50):3098–106.

    Article  Google Scholar 

  23. Chan JA, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30:2963–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kulke MH, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:401–6.

    Article  CAS  Google Scholar 

  25. Saif MW, et al. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. J Pancreas. 2013;14:498–501.

    Google Scholar 

  26. Krug S, Gress TM, Michl P, Rinke A. The role of cytotoxic chemotherapy in advanced pancreatic neuroendocrine tumors. Digestion. 2017;96:67–75.

    Article  CAS  PubMed  Google Scholar 

  27. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.

    Article  CAS  PubMed  Google Scholar 

  28. Krug S, et al. Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms--predictive and prognostic markers for treatment stratification. PLoS One. 2015;10:e0143822.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Efficacy and safety of Everolimus and (STZ-5FU) given one upfront the other upon progression in advanced pancreatic neuroendocrin tumor (pNET) - Full Text View. ClinicalTrials.gov. 2020; https://clinicaltrials.gov/ct2/show/NCT02246127.

  30. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139–43.

    Article  CAS  PubMed  Google Scholar 

  31. Okusaka T, et al. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. J Hepato-Biliary-Pancreat Sci. 2015;22:628–33.

    Article  Google Scholar 

  32. Falconi M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71.

    Article  CAS  PubMed  Google Scholar 

  33. Steven Stricker P. From chemotherapy to targeted therapies: current treatment of carcinoid tumors and pancreatic neuroendocrine tumors. 2011.

    Google Scholar 

  34. Fiore F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47:177–82.

    Article  CAS  PubMed  Google Scholar 

  35. Rossi S, et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas. 2014;43:938–45.

    Article  PubMed  Google Scholar 

  36. Oleinikov K, et al. Endoscopic ultrasound-guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104:2637–47.

    Article  PubMed  Google Scholar 

  37. Barthet M, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019;51:836–42.

    Article  PubMed  Google Scholar 

  38. Park DH, et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc. 2015;48:158–64.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kulke MH, et al. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol. 2015;33:4005.

    Article  Google Scholar 

  40. Hobday TJ, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1551–6.

    Article  CAS  Google Scholar 

  41. Raymond E, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  42. Faivre S, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28:339–43.

    Article  CAS  PubMed  Google Scholar 

  43. Lahner H, et al. Sunitinib efficacy in patients with advanced pNET in clinical practice. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2016;48:575–80.

    Article  CAS  Google Scholar 

  44. Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, Tafuto S, Raj N, Campana D, et al. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed. Ann Oncol. 2018;29:467–8.

    Article  Google Scholar 

  45. Ott PA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:318–27.

    Article  Google Scholar 

  46. Strosberg J, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:2124–30.

    Article  CAS  Google Scholar 

  47. Halperin DM, et al. A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). J Clin Oncol. 2020;38:619.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Abhishek Chouthai

  2. Rutgers, Robert Wood Johnson Medical School, Department of Internal Medicine, New Brunswick, NJ, USA

    Michael Makar

  3. Rutgers State University, New Brunswick, NJ, USA

    Avik Sarkar

Authors
  1. Abhishek Chouthai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Makar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Avik Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avik Sarkar .

Editor information

Editors and Affiliations

  1. Medical Director, Capital Health Medical Center Hopewell, Pennington, NJ, USA

    Cataldo Doria

  2. Capital Health Center for Digestive Health, Pennington, NJ, USA

    Jason N. Rogart

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Chouthai, A., Makar, M., Sarkar, A. (2021). Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). In: Doria, C., Rogart, J.N. (eds) Hepato-Pancreato-Biliary Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-37482-2_39-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-37482-2_39-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-37482-2

  • Online ISBN: 978-3-030-37482-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation